[HTML][HTML] Pathophysiology of chemotherapy-induced peripheral neuropathy

H Starobova, I Vetter - Frontiers in molecular neuroscience, 2017 - frontiersin.org
Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several
antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment …

[HTML][HTML] Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment

S Triarico, A Romano, G Attinà, MA Capozza… - International journal of …, 2021 - mdpi.com
Vincristine-induced peripheral neurotoxicity (VIPN) is a very common side effect of
vincristine chemotherapy among pediatric patients with cancer. Neuropathy may be sensory …

[HTML][HTML] A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy

Y Fukuda, Y Li, RA Segal - Frontiers in neuroscience, 2017 - frontiersin.org
Chemotherapeutic agents cause many short and long term toxic side effects to peripheral
nervous system (PNS) that drastically alter quality of life. Chemotherapy-induced peripheral …

Drug-induced peripheral neuropathy: a narrative review

MR Jones, I Urits, J Wolf, D Corrigan… - Current clinical …, 2020 - ingentaconnect.com
Background: Peripheral neuropathy is a painful condition deriving from many and varied
etiologies. Certain medications have been implicated in the iatrogenic development of Drug …

Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment

B Islam, M Lustberg, NP Staff, N Kolb… - Journal of the …, 2019 - Wiley Online Library
Vinca alkaloids, thalidomide, and eribulin are widely used to treat patients with childhood
acute lymphoblastic leukemia (ALL), adults affected by multiple myeloma and locally …

[HTML][HTML] Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release

H Starobova, M Monteleone, C Adolphe… - Journal of Experimental …, 2021 - rupress.org
Disclosures: K. Schroder reported" other" from Inflazome Ltd outside the submitted work; in
addition, K. Schroder had a patent to PCT/EP2017/053498 licensed (Inflazome Ltd), a patent …

Sequential targeting in crosslinking nanotheranostics for tackling the multibarriers of brain tumors

H Wu, H Lu, W Xiao, J Yang, H Du, Y Shen… - Advanced …, 2020 - Wiley Online Library
The efficacy of therapeutics for brain tumors is seriously hampered by multiple barriers to
drug delivery, including severe destabilizing effects in the blood circulation, the blood–brain …

New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer

Y Zhang, SH Yang, XL Guo - Biomedicine & pharmacotherapy, 2017 - Elsevier
Nowadays, lung cancer, as a health problem in worldwide, has high mortality both in men
and women. Despite advances in diagnosis and surgical techniques of lung cancer in recent …

Pharmacogenomics of vincristine‐induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes

GEB Wright, U Amstutz, BI Drögemöller… - Clinical …, 2019 - Wiley Online Library
Vincristine is an effective chemotherapeutic drug for various cancers, including acute
lymphoblastic leukemia (ALL). Unfortunately, clinical utility is restricted by dose‐limiting …

[HTML][HTML] Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients

S Barnett, F Hellmann, E Parke, G Makin… - European Journal of …, 2022 - Elsevier
Background The anticancer drug vincristine is associated with potentially dose-limiting side-
effects, including neurotoxicity and myelosuppression. However, there currently exists a lack …